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ABSTRACT: A wide range of prescreening tests for antimicrobial
activity of 59 bacterial isolates from sediments of Ria Formosa
Lagoon (Algarve, Portugal) disclosed Vibrio spartinae 3.6 as the
most active antibacterial producing strain. This bacterial strain,
which has not previously been submitted for chemical profiling,
was subjected to de novo whole genome sequencing, which aided in
the discovery and elucidation of a prodigiosin biosynthetic gene
cluster that was predicted by the bioinformatic tool KEGG
BlastKoala. Comparative genomics led to the identification of a
new membrane di-iron oxygenase-like enzyme, annotated as
Vspart_02107, which is likely to be involved in the biosynthesis
of cycloprodigiosin and analogues. The combined genomics−
metabolomics profiling of the strain led to the isolation and
identification of one new branched-chain prodigiosin (5) and to the detection of two new cyclic forms. Furthermore, the evaluation
of the minimum inhibitory concentrations disclosed the major prodigiosin as very effective against multi-drug-resistant pathogens
including Stenotrophomonas maltophilia, a clinical isolate of Listeria monocytogenes, as well as some human pathogens reported by the
World Health Organization as prioritized targets.
The family of tripyrrole red pigments, prodiginines, haveattracted considerable research interest over the last few
decades due to their wide range of bioactivities, which include
antibacterial, antifungal, antiprotozoal, and antimalarial ac-
tions.1 In particular, the immunosuppressant action of natural
or synthetic prodiginines2 has been well investigated, and they
have a distinctly different immunomodulatory mechanism than
that of cyclosporine. Moreover, they are effective pro-apoptotic
agents at nontoxic concentrations.3−6 Extensive medicinal
chemistry optimization of the natural molecules led to the
development of a synthetic derivative, obatoclax mesylate
(GX15-070), which has been shown to modulate autophagy
and has been used in multiple phase I and II combinatorial
cancer chemotherapeutics.7,8 Prodiginines owe their name to
their connection with an important miracle of the Christian
church, i.e., “The Miracle of Bolsena” (1263): A priest fighting
against his decreasing faith received a “prodigious” sign during
a Mass when blood started dripping from the holy bread. A few
centuries later, the Miracle of Bolsena was explained by the
fermentation of the bacterium Serratia marcescens on bread,
associated with the production of a red pigment.9,10
Prodigiosin production was first reported for Serratia
marcescens and then subsequently identified in a variety of
terrestrial and marine Gram-positive and Gram-negative
microorganisms including Pseudomonas magnesiorubra, Hahella
chejuensis, Zooshikella rubidus, Streptomyces spp., and Nocardia
spp.11−14 Other bacteria such as Pseudoalteromonas rubra,
Vibrio gazogenes, and Zooshikella rubidus are able to synthesize
cycloprodigiosin in addition to prodigiosin.13,15,16 Despite the
large number of natural producers, there is only minor
chemical diversity associated with natural prodiginines. They
fall into two broad groups: (1) linear alkyl chain derivatives
exemplified by prodigiosin (1) and undecylprodigiosin and (2)
cyclic derivatives of prodiginines, such as cycloprodigiosin (2)
and streptorubin B.2,9,17 The ubiquitous presence of
prodiginines in phylogenetically distant bacterial strains
seems to indicate a physiological role of these pigments,
although the actual role, as for many natural products, is still
unclear. The antimicrobial activity of purified prodiginines has
been reported in relation to common Gram-positive and
Gram-negative bacterial strains such as Staphylococcus aureus,
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Escherichia coli, and Bacillus subtilis.1,18,19 Analysis of the
structure−function relationship of linear and cyclic prodigi-
nines suggests the latter have an enhanced conformational bias
toward the interaction with a biological target, which in some
cases is associated with increased activity, although no
scientific consensus yet exists.15
In the context of screening for bioactive metabolites from
marine microorganisms, herein, we report on the chemical and
biological investigation of a new prodigiosin producer, Vibrio
spartinae, recently described as a new bacterial species.20 The
bacterium was selected among 59 isolated bacteria from
sediments collected in the Ria Formosa lagoon (Algarve,
Portugal), for their powerful inhibitory activity exhibited
during prescreening for antimicrobial activity against four
human pathogens. The study resulted in an almost completely
annotated genome of V. spartinae, the isolation of both
prodigiosin and cycloprodigiosin as major compounds, and the
isolation of the first example of a branched-chain prodigiosin,
biosynthesized by prodigiosin (pig) biosynthetic gene cluster
(BGC). Furthermore, through an integrated approach that
involved HR-MSn experiments and comparative genomics, the
strain was shown to express an alkylglycerol monooxygenase-
like enzyme encoded by Vspart_02107, which is a homologue
of PRUB680, recently reported from P. rubra. The enzyme
likely catalyzes the final cyclization step from prodigiosin to
cycloprodigiosin, and it appears to regioselectively catalyze the
cyclization of all the linear prodigiosins to their corresponding
cyclic derivatives.
A wide-range screening for antimicrobial activity of the
isolated molecules revealed that the major prodigiosin is
particularly effective against Listeria monocytogenes, the
causative agent of listeriosis,21 and Stenotrophomonas malto-
philia, one of the leading drug-resistant hospital-associated
pathogens.22
■ RESULTS AND DISCUSSION
Selection, Identification, and Genome Character-
ization of the Vibrio spartinae 3.6. Recently, in the
framework of the EMBRIC Transnational Access program
(http://www.embrc.eu/projects/embriceuropean-marine-
biological-research-infrastructure-cluster), a total of 24 sedi-
ments (Supporting Information, Table S1) were collected from
four different points (six replicates each) located in the Ria
Formosa lagoon (Algarve, Portugal). The natural park of Ria
Formosa is a complex of shallow water and lagoons, known for
high fluctuations in tide and high salinity,23 which makes this
environment suitable for the isolation of interesting micro-
organisms. From these sediments, 59 bacterial strains were
isolated and subjected to prescreening for antimicrobial activity
on agar plates. The representative pathogenic strains included
in the screening were three Gram-negative strains (Pseudomo-
nas aeruginosa PAO1, Escherichia coli ATCC 25922, and
Acinetobacter baumannii 13) and one Gram-positive strain
(Staphylococcus aureus ATCC 6538P). Out of the five active
bacteria identified from sediments, the pink bacterial strain
labeled 3.6 (isolated from sediment 7B) showed a pronounced
lytic halo toward all of the strains with the exception of P.
aeruginosa (Table S2) and was therefore selected for further
investigation. The complete 16S rRNA gene was extracted
from the fully assembled genome of V. spartinae 3.6 and was
compared to the nonredundant (nr) database at NCBI limiting
the search to type material. They shared 99.25% similarity to V.
spartinae SMJ21T with SMJ21T=CECT 9026T=LMG
29723T.20 Whole genome sequencing (WGS) of V. spartinae
3.6 yielded a genome of 5.0 Mbp distributed between two
bacterial chromosomes of 3.8 and 1.2 Mbp, respectively, with a
GC content of 45.5%. No further plasmids were detected.
Prokka predicted 4320 protein-coding sequences, 90 tRNA
and 25 rRNA genes (Table 1).
To taxonomically delineate V. spartinae 3.6, pairwise
comparisons were conducted using the Type Strain Genome
Server (TYGS), which showed 93% digital DNA−DNA
hybridization (dDDH) to V. spartinae SMJ21T, the closest
related type strain to V. spartinae 3.6. The probability that this
value is correct was confirmed by the confidence interval that
was between 91% and 94% by linear regression. The threshold
for correct taxonomic assignment using dDDH is ≥70% for
species classification. Therefore, based on these results it was
concluded with a high degree of confidence that isolate 3.6 can
be correctly assigned to V. spartinae.24 Here, we see the user
strain “Vibrio” is contained within the same species cluster as
the type strain V. spartinae SMJ21T=CECT 9026T=LMG
29723T (Figure 1).
Primary metabolism of the isolate was reconstructed from
genome sequence data (translated amino acids) using KEGG
BlastKoala.25 These data were then used to predict (in silico)
the biosynthetic pathway of prodigiosin (Figure S1). There-
after, we confirmed the BGC of V. spartinae 3.6 by comparative
genomics using the prodigiosin BGC from S. marcescens
(GenBank accession number AJ833001.1) as the reference.
Within the genome of V. spartinae 3.6 we discovered the
presence of pigB−pigN as a complete gene cluster, while C-
terminal similarity to pigA can be found within Vspart_03968
Table 1. Genome Attributes of De Novo WGS of Vibrio
spartinae 3.6
attribute value
genome size (bp) 5 010 010
DNA G+C content (bp) 45.5
number of contiguous sequences 2
extrachromosal elements (plasmids) 0
total genes 4520
coding sequences (CDS) 4320
signal peptides 318
tRNA genes 90
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located separately on the second chromosome (Figure S2), but
this might also be a result of its high sequence similarity to the
Acyl-CoA dehydrogenase Adh.
Chemical Identification of Prodigiosins. V. spartinae 3.6
was grown in 200 mL of MB mod liquid media at 20 °C for 3
days, and the intracellular and extracellular extracts were
mixed, dissolved in mass grade MeOH at a concentration of 1
mg/mL, and analyzed using LC-HRMS in positive mode.
The total ion chromatogram (TIC) shown in Figure 2
highlights the presence of two major peaks, peak B and peak D,
respectively, with [M + H]+ of 322.1914 and 324.2071, which
are compatible with the pink pigment prodigiosin (1), first
isolated from Serratia marcescens2 and cycloprodigiosin (2), its
cyclic homologue, respectively. The remaining peaks, visible in
the LC traceA, C, E, F, and Gshowed protonated
molecules [M + H]+ at m/z 296.1756, 336.2070, 350.2227,
338.2227, and 352.2383, respectively.
The peaks A, F, and G showed molecular weights
corresponding to prodigiosin derivatives with C3-, C6-, and
C7-alkyl side chains at the 4″ position. Prodigiosin analogues
with different alkyl side chains have already been reported in
Zooshikella rubidus,13 Pseudoalteromonas rubra,26 and other
Vibrio spp.,15 although in some cases the structures were only
deduced on the basis of ESIMS data. On the other hand, the
molecular weights of peaks C and E indicated one additional
unsaturation degree with respect to the peaks F and G.
In order to confirm the results of the LC-HRMS chemical
profiling and to assess the antimicrobial activity of the pure
prodigiosin components, a large-scale optimized fermentation
was established in the same liquid media, and an extract of
about 600 mg was prepared and was subjected to repeated
solvent partitioning. A preliminary purification by HPLC
fractionation gave the major components, prodigiosin (1) and
cycloprodigiosin (2), and three enriched fractions, which were
further purified by HPLC to isolate the compounds in peaks A,
F, and G. Unfortunately, due to their low abundance and to the
presence of some UV-undetectable contaminations, it was
impossible to obtain sufficiently purified compounds from
peaks C and E for NMR characterization. NMR analysis of the
compounds in peaks A, B, D, and F (Table S4) confirmed their
identity as 4″-propylprodigiosin (3), cycloprodigiosin (2),
prodigiosin (1), and 4″-hexylprodigiosin (4).15
The absolute configuration of naturally occurring cyclo-
prodigiosin remained unknown for a long time. Only recently,
the enantioselective total synthesis of both enantiomers and a
combination of X-ray and chiral-phase HPLC analyses allowed
Figure 1. Genome BLAST distance phylogeny (GBDP) by WGS data
of V. spartinae 3.6. The phylogenetic tree has been inferred from
GBDP distances calculated from genome sequences within the Type
Strain genome server (tygs.dsmz.de). The numbers below the
branches are GBDP pseudobootstrap support values from 100
replications, with an average branch support of 63.6%. The tree was
rooted at the midpoint.
Figure 2. ESI positive mode total ion chromatogram (TIC) of the Vibrio spartinae 3.6 MeOH extract.
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for the determination of the natural cycloprodigiosin from P.
rubra ATCC 29570, as a scalemic mixture occurring in an
enantiomeric ratio of 83:17 (R)/(S).27
Accordingly, when we subjected cycloprodigiosin (2) from
V. spartinae 3.6 to chiral-phase HPLC analysis, a comparable
ratio was observed (Figure S4).
The molecular formula of compound 5 was deduced as
C22H29N3O based on the protonated molecule [M + H]
+ at m/
z 352.2383 in conjunction with 1H and 13C spectroscopic data.
The HRESI MS/MS spectrum showed the fragment ion at m/
z 252.1130, due to the loss of the side chain, which is a
fingerprint of the linear prodigiosins, suggesting a core
prodiginine structure with a seven-carbon side chain.28 The
1H and 13C NMR analysis gave a total match for the signals
relative to the prodigiosene nucleus (Table 2), and this was
confirmed by 2D NMR analysis. However, in the 1H NMR
spectrum, the usual terminal methyl triplet signal was replaced
by a doublet at δH 0.88 integrating for six protons. This finding,
together with the relative corresponding 13C NMR chemical
shift value (δC 22.4) as determined by the analysis of the
HSQC spectrum, was indicative of an isopropyl terminal
subunit. The assignment of the chemical shift values of the
seven carbon branched 4″-methylhexyl side chain was
straightforward and established by the analysis of 2D COSY,
HSQC, and HMBC spectra. For the new compound 5 we
propose the name isoheptylprodigiosin.
There are other examples of branched side chain derivatives
in the prodiginine pigment family, i.e., cyclic prodigiosins R1
and R2 and linear 11-methyldodecylprodigininine.29,30 How-
ever, the biosynthesis of the above compounds, isolated from
Streptomyces griseoviridis, involved the red (23 genes) gene
cluster, characteristic of Gram-positive Streptomyces spp.,2
which is distinct from the pig gene cluster (17 genes) in the
Gram-negative Serratia spp., responsible for prodigiosin
biosynthesis. The isolation of isoheptylprodigiosin (5) from
the Gram-negative V. spartinae 3.6 represents the first report of
a branched-chain prodigiosin arising from the pig gene cluster.
In particular, in the red gene cluster, the constitution of an alkyl
side chain on the right monopyrrole ring is related to the
substrate loading selectivity of RedP, and the replacement by
plasmid-based bioengineering of the RedP’s function with a
Streptomyces FAS FabH31 was reported to produce branched-
chain prodiginines related to undecylprodigiosins. On the
other hand, in the pig gene cluster, the length and the
constitution of the side chain on the right methyl-alkyl-pyrrole
subunit is influenced by the loading of different 2-alkenoyl
CoAs by the thiamine diphosphate-dependent pigD.32
Probably, the pigD homologue in V. spartinae 3.6
Vspart_01681 is able to load 8-methyl-2-nonenoylCoA,
which in turn could be derived from the metabolism of an
iso-fatty acid arising from a branched-chain starter unit (Figure
3).
Vibrio spartinae 3.6 Is Able to Regiospecifically
Catalyze Linear Prodigiosin Cyclization. Thus far, two
unclustered biosynthetic genes have been reported to be
responsible for the final transformation of prodiginine linear
precursors to their cyclic congeners. In Streptomyces spp. the
cyclization reaction used to produce cyclic prodiginine
derivatives, such as streptorubin B, metacycloprodigiosin,
marineosin, prodigiosin R1, and roseophilin, occurs through
the action of enzymes belonging to the family of Rieske
oxygenases, which are exemplified by REDG in Streptomyces
coelicolor.33,34 On the other hand, recent studies on the Gram-
negative P. rubra DSM 6842 = ATCC 29570 genome16
disclosed a completely unrelated alkylglycerol monooxygenase-
like enzyme, di-iron oxygenase encoded by PRUB680, which
was responsible for the regiospecific C10″-H activation and
cyclization of prodigiosin to cycloprodigiosin in P. rubra.16
Interestingly, when the whole genome sequence of V. spartinae
3.6 was compared to REDG and PRUB680, no match was
found with REDG. However, comparison with PRUB680
(GenBank accession no. ERG47138.1) identified a gene,
Vspart_02107 (Figure 4), that shared 81% similarity at the
amino acid level with PRUB680 based on BLASTP analysis.
Moreover, the fatty acid hydroxylase encoded by this gene
displayed the conserved histidine motif, which is known to be
essential for both iron binding and catalysis,35,36 and a similar
transmembrane topology (Figure S3). Again, the observed
incomplete enantioselectivity in the carbocyclization process is
another common feature.
A careful analysis of the HR-MSMS fragmentation pattern of
the minor prodigiosin-like compounds, which featured one
additional unsaturation degree (peaks C and E in Figure 2),
revealed the absence of the key fragment m/z 252.1131 due to
the loss of the alkyl side chain at C-4″, a common feature of all
linear prodigiosins; additionally, the common fragments C and
D+B suggested a common six-membered cycloprodigiosin-like
Table 2. 1H (400 MHz) and 13C (125 MHz) NMR
Assignment of Isoheptylprodigiosin, 5 (CDCl3
a)
isoheptylprodigiosin (5)b
position δC, type δH (J in Hz) COSY HMBC
c
NH1 12.4, br s 2, 3, 4
2 127.2, CH 7.25, br s NH1, 3 3, 4, 5
3 111.9, CH 6.36, br s NH1, 2, 4 5




3′ 92.9, CH 6.08, s NH1′ 2′, 5′
O-Me 58.7 4.01, s 4′
4′ 166.3, C
5′ 121.8, C
6′ 116.1, CH 6.95, s NH1′ 4′, 3″
NH1″b 12.58d 3″
2″ 126.4, C
3″ 128.6, CH 6.67, m NH1″, 6″, 7″ 2″, 5″
4″ 128.9, C
5″ 146.9, C
6″ 12.4, CH3 2.52, s 3″ 4″, 5″
7″ 25.3, CH2 2.41, t (7.5 Hz) 3″, 8″ 4″, 5″, 8″
8″ 30.1, CH2 1.52d 7″, 9″
9″ 26.9, CH2 1.31, m 8″, 10″
10″ 38.8, CH2 1.19, m 9″, 11″
11″ 27.8, CH 1.50d 12″, 13″
12″
13″ 22.4, CH3 0.88, d (6.6 Hz) 11″ 11″, 10″
aNMR solvent was established for comparative purpose with
literature data and to detect exchangeable protons, despite low
solubility observed for the compound in this solvent. bHPLC
conditions furnished pure compound in the protonated form.
cHMBC correlations are from the proton(s) stated to the indicated
carbon. dOverlapped with other signals.
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core, whereas fragments A and D, which differed from each
other by +14 amu, were indicative of the presence of
homologous side chains at the C-10″ position. Further
fragmentation of the daughter fragments A gave the common
third-generation fragment m/z 146.0962, due to the loss of the
side chain on the cycloprodigiosin core. On the basis of these
data, the structures for the compounds correlating to peaks C
and E were tentatively assigned as indicated in Table 3, leaving
the constitution of the three carbon side chains undetermined,
although the iso-propyl chain should be preferred on the basis
of biogenetic consideration. This HRMSn-comparative ge-
nomics approach, highlighted the feature of the fatty acid
hydroxylase (Vspart_02107) to catalyze the regiospecific
oxidative cyclization of all the linear prodigiosins to their
corresponding six-membered cyclic derivatives, irrespective of
their side chain length. This catalytic capability appears to be a
distinctive feature of this enzyme, which is unrelated to
previously described proteins involved in the biosynthesis of
cyclic prodigiosin-like derivatives.
Antimicrobial Activities of Pure Molecules. As
reported in the literature, the data on the antimicrobial activity
on prodigiosins, mainly cycloprodigiosin and prodigiosin are
dated and very limited.19 In the present study, we evaluated the
antimicrobial potential of the new isoheptylprodigiosin (5),
together with the major compounds isolated, prodigiosin (1)
and cycloprodigiosin (2), against a wide range of human
pathogens. Some of the targeted pathogens used in this assay
were from the WHO Priority list of pathogens for which new
antibiotics are urgently needed,37 while others are emergent
pathogens. A clinical isolate of L. monocytogenes was used
Figure 3. Linear prodigiosins from Vibrio spartinae 3.6 (m/z, [M + H]+) and their biosynthetic origins.
Figure 4. Linear display of PRUB680 and its neighbor PRUB_00675 found in P. rubra DSM 6842, in comparison with their homologues in V.
spartinae 3.6, Vspart_02107, and Vspart_02106.
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during the antibacterial assay; this bacterium is a foodborne
pathogen that is the causative agent of listeriosis, one of the
most serious and severe foodborne diseases.38 This pathogen is
developing resistance to many antibiotics commercially in
use;39 particularly, the strain used during this assay was isolated
from the cerebrospinal fluid of an infected patient. Three
strains of S. maltophilia were also used, as it is one of the
leading drug-resistant nosocomial-associated pathogens.22 The
majority of the clinical isolate strains have developed resistance
to multiple agents used to treat Gram-negative bacterial
infections.40,41 The three pigments showed activity toward
both Gram-positive and Gram-negative strains, with prodigio-
sin (1) showing the lowest MIC values (1.3−3.3 μg/mL) and
being approximately 2-fold more active than cycloprodigiosin.
The MIC and MIC50 values are reported in Table 4.
The MIC values against Staphylococcus species conform with
previous presented data.19,42 The antibacterial activity toward
L. monocytogenes was compared to ampicillin, which is
currently used alone or mixed with gentamicin as the drug of
choice for listeriosis treatment,43−45 and the MIC value of 1
was comparable with the positive control. Moreover, the three
prodigiosins were tested on three different S. maltophilia
strains; also in this case, prodigiosin (1) displayed the best
MIC values (1.7−2.7 μg/mL). Among the tested compounds,
isoheptylprodigiosin (5) displayed higher MIC values toward
all the tested strains.
It is also worth noting the ability of these pigments to inhibit
50% of bacterial growth at sub-MIC concentrations, in
particular of Gram-positive pathogens.
Noteworthy is the antimicrobial activity of 1 against L.
monocytogenes and S. maltophilia, particularly as they are the
causative agents of difficult to treat infections that urgently
require new antibiotic molecules to counteract them.
Herein, we provide a deep elucidation of the structure−
function properties of these novel molecules. In particular, the
steric hindrance represented by the presence of a branched
chain in the isoheptylprodigiosin (5) and of the condensed
cycle in the cycloprodigiosin (2) negatively affects their
inhibitory capacity.
In conclusion, the whole genomic analysis of the marine
bacterial strain V. spartinae 3.6, isolated from the sediments of
the Rio Formosa lagoon in Portugal, and the metabolic
pathway prediction revealed the presence of a prodigiosin
BGC. Complete dereplication of the metabolic profile by
HRESIMS and NMR analysis led to the identification of five
prodigiosins, including the first example of a branched-chain
prodigiosin derivative arising from a pig gene cluster. The
production of the branched-chain molecule was assigned to the
peculiar substrate flexibility of the pigD homologue in the
prodigiosin biosynthetic gene cluster of V. spartinae 3.6.
Analogously, the presence of two further homologues of
cycloprodigiosin together with a high % of cycloprodigiosin
Table 3. HRESIMS Analysis of Peaks B, C, and E
MS1
(m/z) MS2 fragment ions (m/z)
R [M + H]+ fragment A fragment C fragment D fragment E
fragment
D+B




CH3 322.1914 160.1119 175.0864 307.1676 290.1653 292.1446 146.0962
C20H24N3O C11H14N C10H11N2O C19H21N3O C19H20N3 C18H18N3O C10H12N
peak C C2H5 336.2070 174.1275 175.0863 321.1832 304.1806 292.1442 146.0961
C21H26N3O C12H16N C10H11N2O C20H23N3O C20H22N3 C18H18N3O C10H12N
peak E C3H7 350.2227 188.1431 175.0863 335.1986 318.1962 292.1441 146.0961
C22H28N3O C13H18N C10H11N2O C21H25N3O C21H24N3 C18H18N3O C10H12N
Table 4. MIC and MIC50 Values (μg mL
−1) for Prodigiosin (1), Cycloprodigiosin (2), and Isoheptylprodigiosin (5) against a
Panel of Human Pathogenic Bacteriaa
antimicrobial activity (μg/mL)
prodigiosin (1) cycloprodigiosin (2) isoheptylprodigiosin (5) positive controlb
MIC MIC50 MIC MIC50 MIC MIC50 MIC
Staphylococcus aureus ATCC 29213 3.3 0.050 4.0 0.060 27 0.50 2.0
Staphylococcus aureus ATCC 23235 1.3 0.060 3.3 0.080 21 0.50 2.0
Staphylococcus aureus 6538P 1.7 0.040 3.3 0.050 21 0.20 1.7
Staphylococcus epidermidis ATCC 35984 2.0 0.33 3.3 0.50 27 2.7 2.0
Listeria monocytogenes MB677 1.7 0.16 4.0 0.40 21 3.3 0.80
Stenotrophomonas maltophilia ATCC 13637 1.7 0.66 3.3 2.0 27 3.3 3.3
Stenotrophomonas maltophilia ATCC 13636 1.7 0.13 3.3 1.0 27 3.3 4.0
Stenotrophomonas maltophilia ATCC 700475 2.7 0.50 5.3 1.7 27 4.0 4.0
aEach experiment was repeated at least three times (n = 3); the mean value is shown in this table. bSee Table S3 in the Supporting Information for
the antibiotics used as positive controls.
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(more than 50% w/w compared with prodigiosin) was
associated with the presence in the Vibrio BGCs of a gene
encoding for a new member of the alkylglycerol monoox-
ygenase-like enzyme, related to PRUB680 in P. rubra. Further
investigation of the catalytic properties of this enzyme could
expand the biochemical toolbox for the chemoenzymatic
transformation of linear precursors of natural and unnatural
molecules into their cyclic counterparts via sp3 C−H
activation, a remarkable process that is often not accessible
via conventional synthetic methods.
■ EXPERIMENTAL SECTION
General Experimental Procedures. UV spectra were recorded
with a a Varian Cary 1E UV/vis double ray spectrophotometer
(Agilent), in MeOH + 0.1% (v/v) trifluoroacetic acid (TFA) at room
temperature. 1D and 2D NMR experiments were recorded on Varian
Inova 700 (Agilent) and Bruker Avance NEO 400 spectrometers with
an RT-DR-BF/1H-5 mm-OZ SmartProbe. Chemical shifts were
reported in δ (ppm) and were referenced to the residual CHCl3 as
internal standards (δH 7.26 and δC 77.0).
The LC-HRMS analysis were carried out on an LTQ XL liquid
chromatography high-resolution mass spectrometry system (LC-
HRMS) (ThermoScientific) equipped with an Accelera 600 pump
HPLC. Purification was performed using a Jasco PU-2089 Plus
quaternary gradient pump connected to a UV-2075 Plus UV/vis
detector equipped with a Waters Rheodine injector for the first
purification step and an Aquity UPLC H-CLASS connected to a PDA
detector (Waters) for the final purification of the minor components.
The 96-well plates were read on a Biotek ELX800, monitoring the
absorbance at 600 nm at room temperature.
Media and Buffers. All reagents and consumables used in
preparation of media were purchased from Conda, Sigma-Aldrich,
Merck, or PanReac unless otherwise stated. Media were prepared in
grams per liter of ddH2O according to the manufacturer’s instructions
and autoclaved at 121 °C at 15 psi. For the solid media,
bacteriological agar was added at 1.7% (w/v).
Cation-Adjusted Mueller-Hinton Broth (CAMHB).46 Marine Broth
(MB): 19.4 g NaCl, 8.8 g/L MgCl2, 5 g/L peptone, 3.24 g/L Na2SO4,
1.8 g/L CaCl2, 1 g/L yeast extract, 0.55 g/L KCl, 0.16 g/L NaHCO3,
0.10 g/L Fe(III) citrate, 0.08 g/L KBr, 0.034 g/L SrCl2, 0.022 g/L
H3BO3, 0.008 g/L Na2HPO4, 0.004 g/L sodium silicate, 0.0024 g/L
NaF, 0.0016 g/L NH4NO3
Tryptone Soy Broth (TSB): 3 g/L papaic digest of soya, 2.5 g/L D-
(+)-glucose, 17 g/L pancreatic digest of casein, 2.5 g/L K2HPO4, 5g/
L NaCl.
Marine Broth modified (MB mod): MB + 10 g/L peptone + 0.3 g/
L K2HPO4.
Luria−Bertani (LB): 10 g/L tryptone, 5 g/L yeast extract, 10 g/L
NaCl.
Nutrient broth (NB): 15 g/L peptone, 6 g/L NaCl, 3 g/L yeast
extract.
Bacterial Strains Isolation. The bacterial strains were isolated
from four sediment sample sites, and six replicates were collected
from each site of the Ria Formosa lagoon (Faro, Portugal) and stored
at −80 °C until analysis; location coordinates and environmental
features are described in Table S1. The rationale for sediment
collection was to obtain samples from different environmental
conditions and at different depths. For the isolation of bacteria, one
gram of each sediment was gently mixed with 3 mL of sterilized water,
and the supernatant was serially diluted (10−1 to 10−3) in sterilized
water. A 100 μL amount of each dilution was plated onto MB and
TSB agar plates. After 20 days of incubation at 20 °C, 59
morphologically different CFUs were selected and inoculated into
MB and TSB liquid media.
Screening for Antimicrobial Activity. A single CFU of each of
the 59 isolates was inoculated into two 96-well plates, the first filled
with 200 μL of MB and the second with TSB, and incubated for 2
days at 20 °C under constant agitation at 120 rpm. Then, the plates
were replicated using a pin replicator into five deep-well plates and
filled with 1.6 mL per well of five different media: MB, MB mod, TSB,
NB, and LB. Finally, the deep wells were incubated at 20 °C for 5
days, under gentle agitation at 120 rpm. After 5 days, each deep well
was replicated onto LB agar plates inoculated with a target pathogenic
strain at a concentration of 0.04 OD600/mL. Pseudomonas aeruginosa
O1,47 Escherichia coli ATCC 25922,48 Staphylococcus aureus ATCC
6538P,49 and Acinetobacter baumannii 1350 were used for these growth
inhibition assays.
For the assessment of antimicrobial activity, the plates were
inoculated at 20 °C for 24 h to allow the growth of the 59 bacteria.
Subsequently, the plates were moved to 37 °C for 24 h to allow the
growth of the pathogens, and finally, the active Ria Formosa strains
were revealed by the formation of an inhibition halo.
De Novo Whole Genome Sequence of Vibrio spartinae 3.6.
DNA was isolated using Qiagen Genomic-tip 100/G according to the
instructions of the manufacturer. A SMRTbell template library was
prepared according to the instructions from PacificBiosciences,
following the Procedure & Checklist − Greater Than 10 kb Template
Preparation. Briefly, for preparation of the 15 kb libraries, 8 μg of
genomic DNA from strain 3.6 was applied unsheared. DNA was end-
repaired and ligated overnight to hairpin adapters applying
components from the DNA/polymerase binding kit P6 from Pacific
Biosciences. Reactions were carried out according to the manufac-
turer′s instructions. BluePippin size-selection to greater than 4 kb was
performed according to the manufacturer’s instructions. Conditions
for annealing of the sequencing primers and binding of polymerase to
a purified SMRTbel template were assessed with the calculator in RS
Remote, PacificBiosciences. One SMRT cell was sequenced per strain
on the PacBio RSII taking one 240 min movie. Libraries for
sequencing on the Illumina platform were prepared applying the
Nextera XT DNA library preparation kit with modifications.51
Samples were sequenced on NextSeq 500. Genome assembly was
performed by applying the RS_HGAP_Assembly.3 protocol included
in SMRT Portal version 2.3.0 applying a target genome size of 10
Mbp. Error correction was performed by mapping the Illumina short
reads onto finished genomes using the Burrows−Wheeler Aligner bwa
0.6.2 in paired-end (sample) mode using default settings,52 with
subsequent variant and consensus calling using VarScan 2.3.6.53
Automated genome annotation was carried out using Prokka.54 The
genome has been deposited at NCBI GenBank under accession nos.
CP046269 and CP046268.
Species Delineation of Vibrio spartinae 3.6 by In Silico Type
Strain Genome Server. The genome sequence data were uploaded
to the TYGS, a free bioinformatics platform available at https://tygs.
dsmz.de, for whole genome-based taxonomic analysis.55 The results
were provided by the TYGS on Oct 2, 2019.
Primary Metabolism Analysis by KEGG BlastKoala. The
amino acid sequences derived from the nucleotide sequences of the V.
spartinae 3.6 genome were analyzed by KEGG BlastKoala by selecting
“Taxonomy group: Prokaryotes, Bacteria” and the KEGG database
searched: “species_prokaryotes.pep” and other default parameters.
KOALA (KEGG orthology and links annotation) is KEGG’s
internal annotation tool for K number assignment of KEGG GENES
using SSEARCH computation. BlastKOALA assigns K numbers to
the user’s sequence data by BLAST searches against a nonredundant
set of KEGG GENES.25
Strain Cultivation and Metabolite Extraction. A single CFU
of V. spartinae 3.6 was used to inoculate 3 mL of liquid MB mod in a
sterile bacteriological tube. After 48 h of incubation at 20 °C at 180
rpm, the preinoculum was used to inoculate 200 mL of the same
media, at an initial optical density of 0.01 at 600 nm. The flask was
incubated for 3 days at 20 °C under constant agitation of 180 rpm.
Metabolites were extracted with acetone and EtOAc from the biomass
and exhausted broth, respectively; then they were mixed together and
evaporated and the obtained extract was dissolved at 1 mg/mL of LC-
MS grade MeOH. Finally, 4 μL of extract was injected to carry out the
chemical profiling. LC-HRMS dereplication utilized the LC-HRMS
instrumentation equipped with an Acquity UPLC BEH C18 1.7 μm
column (Waters). The mobile phase A was composed of 100% LC-
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MS mass grade H2O, and the mobile phase B was composed of 100%
MeCN; both phases were added with 0.1% of LC-MS grade formic
acid.
Isolation and Purification of Compounds. Large-scale
fermentation was obtained by inoculating 1.8 L of MB mod. Pigments
were extracted with the same methodology described above, and in
addition to that, the extract was subjected to a first hexane/MeOH
liquid−liquid partitioning (3 × 100 mL), followed by CHCl3/H2O
extraction (3 × 100 mL). Finally, the organic layer was dried over
anhydrous sodium sulfate, concentrated under reduced pressure, and
lyophilized to give about 300 g of dark extract. The extract was
subjected to a first HPLC fractionation on a Phenomenex Luna
column (5 μm, 10 mm i.d. × 250 mm) using a gradient program (flow
rate 0.3 mL/min; 50 μL injection volume). The mobile phase
consisted of 0.1% TFA in H2O (buffer A) and 0.1% TFA in MeCN
(buffer B), following this gradient program: the initial solvent
condition was 45% solvent B for 5 min; the gradient was then
gradually increased from 45% solvent B to 85% solvent B over 25 min.
Subsequently, solvent B was increased to 100% and was kept at 100%
of B for 10 min before the re-equilibration step. The semipreparative
fractionation gave 14.5 mg of pure cycloprodigiosin (2) and 26.6 mg
of pure prodigiosin (1). The three enriched fractions were subjected
to further UPLC purification on a Phenomenex Luna 5 μm PFP
column (5 μm, 4.6 mm i.d × 250 mm), with an optimized elution
profile using the same solvents A and B as the mobile phases, and
resulted in 2.5 mg of 5″-methyl-4″-propyl prodiginine (3), 0.7 mg of
11″-methyl-4″hexyl prodiginine (4), and 3 mg of isoheptylprodigiosin
(5).
Isoheptylprodigiosin (5): dark pink, amorphous solid; UV
(MeOH, 0.1% TFA) λmax (log ε) 537 (4.3), 512 (4.0), 385 (3.1),
371 (3.1), 296 (3.3); 1H NMR (CDCl3, 400 MHz) and
13C NMR
(CDCl3, 125 MHz) Table2; HRESIMS m/z 352.2383 [M + H]
+
(calcd for C22H30ON3, 352.2383).
Minimal Inhibitory Concentration (MIC) Assessment. The
antimicrobial potential of the pure molecules was assessed by the
determination of the MIC by the microdilution method and
compared with appropriate antibiotics, as described by the Clinical
and Laboratory Standard Institute.46 The tests were performed in
CAMHB. DMSO at an initial concentration of 2% (v/v) was used as
negative control, to establish the effect on the cell growth of the
solvent used to solubilize the compounds. Each compound was
dissolved in DMSO and was 2-fold serially diluted from 32 to 0.015
μg/mL in a final volume of 100 μL of CAMHB, in a 96-well
microtiter plate (Sarstedt). Essentially, each well contained 50 μL of
test compound solution at twice the desired final concentration and
was inoculated with 50 μL of bacterial seed culture grown overnight at
37 °C, yielding a final inoculum of 4 × 105 CFU/mL in a 100 μL final
volume of each well. Finally, each plate was incubated for 20 h at 37
°C. The MIC50 has been calculated as the minimum concentration
that inhibits 50% of cell population growth. The pathogens used in
the screening are listed below: S. aureus ATCC 29213,56 S. aureus
ATCC 23235,57 S. aureus ATCC 6538P,49 S. epidermidis ATCC
35984,58 L. monocytogenes MB677,59 S. maltophilia ATCC 13637,60 S.
maltophilia ATCC 13636,61 and S. maltophilia ATCC 700475.62
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